Michael Seul
University of Texas MD Anderson Cancer Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Michael Seul.
Transfusion | 2005
Ghazala Hashmi; Tasmia Shariff; Michael Seul; Prabhakar Vissavajjhala; Kim Hue-Roye; Dalisay Charles-Pierre; Christine Lomas-Francis; Asok Chaudhuri; Marion E. Reid
BACKGROUND: Typing for blood group antigens is currently performed by hemagglutination. The necessary reagents are becoming costly and limited in availability, and the methods are labor‐intensive. The purpose of this study was to determine the feasibility of the use of large‐scale DNA analysis in a microarray as a substitute for blood group typing.
Transfusion | 2007
Ghazala Hashmi; Tasmia Shariff; Yi Zhang; Joan Cristobal; Chiu Chau; Michael Seul; Prabhakar Vissavajjhala; Christopher Baldwin; Kim Hue-Roye; Dalisay Charles-Pierre; Christine Lomas-Francis; Marion E. Reid
BACKGROUND: A “BeadChip” array permits reliable simultaneous DNA typing of single‐nucleotide polymorphisms for minor blood groups. A high‐throughput DNA analysis was studied as a routine method of phenotype prediction and software was developed to interpret and analyze the large volume of data points.
Transfusion | 2010
Ellen Klapper; Yi Zhang; Priscilla Figueroa; Paul C. Van Ness; James R. Stubbs; Ihab Abumuhor; Jeffrey A. Bailey; Laura Epperson; Craig Tauscher; Ermelina Enriquez; Ghazala Hashmi; Michael Seul
BACKGROUND: Conventional pretransfusion testing uses hemagglutination to ensure donor‐recipient compatibility for ABO/D status and recipient alloantibodies. While screening large numbers of donor units for multiple antigens by hemagglutination is impractical, novel methods of DNA analysis permit the rapid determination of an extended human erythrocyte antigen (xHEA) phenotype. A prospective observational study was conducted at four hospital transfusion services to test an alternative paradigm of identifying xHEA‐typed units for patients in three cohorts by utilizing DNA analysis and a novel inventory management model.
Transfusion | 2010
Ellen Klapper; Yi Zhang; Priscilla Figueroa; Paul C. Van Ness; James R. Stubbs; Ihab Abumuhor; Jeffrey A. Bailey; Laura Epperson; Craig Tauscher; Ermelina Enriquez; Ghazala Hashmi; Michael Seul
BACKGROUND: Conventional pretransfusion testing uses hemagglutination to ensure donor‐recipient compatibility for ABO/D status and recipient alloantibodies. While screening large numbers of donor units for multiple antigens by hemagglutination is impractical, novel methods of DNA analysis permit the rapid determination of an extended human erythrocyte antigen (xHEA) phenotype. A prospective observational study was conducted at four hospital transfusion services to test an alternative paradigm of identifying xHEA‐typed units for patients in three cohorts by utilizing DNA analysis and a novel inventory management model.
Archive | 2011
Ghazala Hashmi; Yi Zhang; Michael Seul
This chapter provides an overview of key elements of the bead array technology and related manufacturing steps as well as key components in the deployment of the BeadChip™ system. The BeadChip™ molecular immunohematology has a spectrum of applications which can utilize multianalyte (multiplex) nucleic acid and protein analysis by Random Encoded Array Detection.
Transfusion | 2009
Ellen Klapper; Yi Zhang; Priscilla Figueroa; Paul C. Van Ness; James R. Stubbs; Ihab Abumuhor; Jeffrey A. Bailey; Laura Epperson; Craig Tauscher; Ermelina Enriquez; Ghazala Hashmi; Michael Seul
BACKGROUND: Conventional pretransfusion testing uses hemagglutination to ensure donor‐recipient compatibility for ABO/D status and recipient alloantibodies. While screening large numbers of donor units for multiple antigens by hemagglutination is impractical, novel methods of DNA analysis permit the rapid determination of an extended human erythrocyte antigen (xHEA) phenotype. A prospective observational study was conducted at four hospital transfusion services to test an alternative paradigm of identifying xHEA‐typed units for patients in three cohorts by utilizing DNA analysis and a novel inventory management model.
Archive | 2003
Ghazala Hashmi; Michael Seul; Joachim Messing
Archive | 2002
Alice Xiang Li; Ghazala Hashmi; Michael Seul
Archive | 2006
Ghazala Hashmi; Michael Seul; Joachim Messing
Archive | 2004
Ghazala Hashmi; Michael Seul